Arid1a mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

HIGHLIGHTS

• who: Radia M. Johnson from the Clinic, Rochester, MN, USA Guardant Health, Inc, Redwood City, CA, USA. University of California, San Francisco, San Francisco, CA, USA. University of have published the article: ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer, in the Journal: (JOURNAL) of 19/08/2021
• what: The authors show that anti-EGFR but not antiVEGF treatment enriches for emerging ARID1A in CRC patients. Nature Communications | 13:5478 __NEWPAGE__Article (CALGB)/SWOG 80405 trial and other relevant CRC datasets here the authors investigate additional mechanisms of resistance to anti . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.